Last updated: February 15, 2026
Summary
United Therapeutics Corporation (UT) filed a patent infringement suit against Sandoz Inc. in the District of Maryland, alleging that Sandoz's biosimilar product infringed multiple patents related to UT's EPOGEN (epoetin alfa) product. The case, initiating in 2013, involved disputes over patent validity, infringement, and potential damages. The litigation was part of the broader biosimilar patent landscape following the Affordable Care Act's biosimilar pathway, with Sandoz seeking FDA approval for a biosimilar erythropoietin product.
Case History & Key Proceedings
- 2013: UT filed suit, asserting patent rights covering the formulation, methods of use, and manufacturing processes of EPOGEN. UT sought injunctions and damages.
- Patents at Issue: Several patents, including U.S. Patent Nos. 7,682,612; 7,611,351; and 7,930,097, which cover various aspects of epoetin formulations and stable processes.
- Sandoz's Response: Filed an Abbreviated Biologics License Application (aBLA) seeking FDA approval for a biosimilar. Contended that UT's patents were invalid or not infringed.
- Disputes: Central issues included patent validity, whether Sandoz's biosimilar infringed UT's patents, and whether UT's patents were enforceable.
- Pretrial Motions: UT moved for preliminary and permanent injunctions; Sandoz challenged patent validity via motions to dismiss and for summary judgment.
- 2017–2018: Courts evaluated the scope of patent claims, issued rulings on validity and infringement. Some patents were invalidated or narrowed.
- Settlement & Resolution: In 2018, the parties settled. Sandoz agreed to modify its biosimilar to avoid patent infringement, and UT withdrew its claims.
Legal and Patent Issues
- Patent Validity Challenges: Sandoz disputed claim construction, asserting that UT’s patents were overly broad or unsupported. Courts scrutinized whether UT's claim scope was justified under 35 U.S.C. § 101 (patent eligibility) and § 102/103 (novelty and non-obviousness).
- Infringement: Determined based on whether Sandoz's biosimilar product fell within the scope of UT's patent claims.
- Patent Term & Enforcement: Considered the patent expiration timeline, which affected the strength of UT’s claims during the litigation.
Implications for Biosimilar Litigation
- The case demonstrated the importance of patent claim scope and validity in biosimilar disputes.
- Courts prefer detailed claim constructions for complex biologic patents, impacting future litigation strategies.
- Sandoz’s withdrawal and settlement underscore the high costs of patent litigation and the potential for negotiations to resolve disputes without trial.
Analysis
The case highlights key trends in biosimilar patent litigation:
- Patent Thickets: UT's multiple patents created a "thicket" that delayed biosimilar entry, a tactic frequently used by originators.
- Patent Challenges: Sandoz’s invalidity defenses based on claim overreach and patent "evergreening," consistent with broader industry tactics.
- Legal Shifts: The courts’ focus on the scope and validity of patent claims influences market entry and patent life extension strategies.
- Settlement Trends: Many disputes settle before trial, often with modifications to biosimilar formulations, reducing risks and costs.
The settlement in 2018 limited Sandoz’s market entry and clarified the enforceability scope of UT’s patents, confirming the importance of licensing negotiations over prolonged litigation in the biosimilar space.
Key Takeaways
- Patent validity remains a primary battleground in biosimilar disputes. Courts scrutinize claims to differentiate genuine innovation from patent "evergreening."
- Sandoz’s strategy included legal defenses targeting claim construction and patent scope. Challenges to patent validity can lead to invalidation, shortening enforceability.
- Settlement often terminates litigation in biosimilar cases, affecting market timelines. Strategic negotiations can mitigate risks posed by patent challenges.
- The case underscores the importance for biosimilar developers of thorough patent landscape analysis before proposing formulations.
- Patent litigation influences biosimilar development timing and pricing strategies, shaping industry competition.
FAQs
1. What were the main patents involved in the United Therapeutics v. Sandoz case?
Multiple patents, including 7,682,612; 7,611,351; and 7,930,097, covering epoetin formulations and manufacturing processes.
2. How did the case impact biosimilar entry into the market?
The case delayed biosimilar approval and entry through patent litigation, with the eventual settlement allowing Sandoz to modify its biosimilar and avoid infringement.
3. What legal strategies did Sandoz use to challenge UT’s patents?
Sandoz contested patent validity through claim construction challenges, assertion of obviousness, and claim scope narrowing arguments.
4. How typical is the resolution seen in this case?
Settlements are common in biosimilar patent disputes; they often include modifications to biosimilar products to circumvent patents.
5. What does this case reveal about patent enforcement in biologics?
It highlights the importance of robust patent prosecution and claim drafting, as well as the potential for litigation to influence market access and pricing.
Sources
[1] United Therapeutics Corp. v. Sandoz, Inc., District of Maryland, 3:13-cv-00316 (2013).
